We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.60 | 7.59 | 7.68 | 7.69 | 7.59 | 7.66 | 2,551,609 | 21:30:14 |
From May 2019 to May 2024
By Cristina Roca
Bayer AG (BAYN.XE) has agreed to buy the shares in BlueRock Therapeutics it didn't already own, valuing the company at up to $1 billion, it said Thursday.
Bayer, which already held 40.8% in BlueRock, will buy the remaining shares in the biotechnology company for about $240 million in cash and an additional $360 million in milestone payments. It expects the deal to close during the third quarter of 2019.
The German chemical and pharmaceutical giant established BlueRock, which develops engineered cell therapies in the fields of neurology, cardiology and immunology, through a venture with Versant Venture Management LLC (VV.XX) in 2016.
Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca
(END) Dow Jones Newswires
August 08, 2019 07:29 ET (11:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
